Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Dapagliflozin and Empagliflozin in Myocardial Dysfunction
IRCT20111206008307N45Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dapagliflozin and empagliflozin in heart failure (HF), myocardial infarction (MI) and myocardial dysfunction, sponsored by Tabriz University of Medical Sciences. Started Feb 2024; status: completed.
02
Drugs
dapagliflozinempagliflozin
03
Conditions
heart failure (HF)myocardial infarction (MI)myocardial dysfunction
Beyond the preview
Go deeper on IRCT20111206008307N45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20111206008307N45.